Biocartis (Mechelen, Belgium) announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd., both affiliates of Merck KGaA (“Merck”). The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and North Africa (MEA) region. The Idylla™ KRAS Mutation Test and Idylla™ NRAS-BRAF Mutation Test are highly performant6 Tests that rapidly determine the RAS biomarker status in mCRC tumor tissue samples. Due to the ease-of-use of the Biocartis Idylla™ Platform, the Tests can be deployed in any user setting and in turn aid patient access to biomarker testing globally. In our mission to enable universal access to personalized medicine for patients around the world, Biocartis is proud to provide Idylla™'s cutting-edge technology for mCRC testing across countries in the MEA region.
